Reata Pharmaceuticals Inc (RETA) Sees Unusually-High Trading Volume
Reata Pharmaceuticals Inc (NASDAQ:RETA) shares saw unusually-strong trading volume on Wednesday . Approximately 219,355 shares changed hands during trading, an increase of 68% from the previous session’s volume of 130,459 shares.The stock last traded at $27.45 and had previously closed at $26.45.
Several research analysts recently commented on RETA shares. Piper Jaffray Cos. started coverage on Reata Pharmaceuticals in a research note on Monday, June 20th. They set an “overweight” rating and a $33.00 target price for the company. Cowen and Company started coverage on Reata Pharmaceuticals in a research note on Monday, June 20th. They set an “outperform” rating and a $22.00 target price for the company. Citigroup Inc. started coverage on Reata Pharmaceuticals in a research note on Monday, June 20th. They set a “buy” rating and a $32.00 target price for the company. Finally, Zacks Investment Research raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a research note on Saturday, August 27th.
The stock has a 50-day moving average of $20.26 and a 200-day moving average of $19.22. The firm’s market capitalization is $618.63 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/reata-pharmaceuticals-inc-reta-sees-unusually-high-trading-volume-2.html
Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Thursday, August 11th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $12.40 million for the quarter. Equities analysts predict that Reata Pharmaceuticals Inc will post ($0.54) earnings per share for the current year.
In other news, Director R Kent Mcgaughy, Jr. bought 308,220 shares of the business’s stock in a transaction that occurred on Thursday, August 18th. The shares were acquired at an average cost of $17.08 per share, with a total value of $5,264,397.60. Following the transaction, the director now owns 25,004 shares of the company’s stock, valued at approximately $427,068.32. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Cpmg Inc bought 73,403 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The stock was purchased at an average cost of $19.26 per share, for a total transaction of $1,413,741.78. Following the completion of the transaction, the director now directly owns 113 shares in the company, valued at approximately $2,176.38. The disclosure for this purchase can be found here.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.